Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544750 | 0.92 | EGFR (0.40) | EGFRERBB3DUS2ERBB2FGFR1 | |
| SCHEMBL29544843 | 0.90 | FGFR1 (0.38) | EGFRERBB2FGFR1BTKITK | |
| SCHEMBL29544572 | 0.89 | EGFR (0.40) | EGFR | |
| SCHEMBL29544700 | 0.87 | EGFR (0.40) | EGFR | |
| SCHEMBL29544798 | 0.84 | EGFR (0.38) | EGFRKDR | |
| SCHEMBL29544580 | 0.83 | TYK2 (0.37) | EGFRERBB2FGFR1FGFR4 | |
| SCHEMBL29544468 | 0.82 | EGFR (0.41) | EGFR | |
| SCHEMBL29544758 | 0.81 | EGFR (0.39) | EGFR | |
| SCHEMBL29544955 | 0.80 | EGFR (0.39) | EGFRKDR | |
| SCHEMBL29545142 | 0.80 | CSF1R (0.39) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |